New anticoagulants for the prevention of venous thromboembolism by Becattini, Cecilia et al.
© 2010 Becattini et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Drug Design, Development and Therapy 2010:4 49–60
Drug Design, Development and Therapy
R E V I E W
open access to scientific and medical research
Open Access Full Text Article
49
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
New anticoagulants for the prevention 
of venous thromboembolism
Cecilia Becattini
Alessandra Lignani
Giancarlo Agnelli
Internal and Cardiovascular 
Medicine and Stroke Unit,  
University of Perugia, Italy
Correspondence: Cecilia Becattini
Internal and Cardiovascular Medicine and 
Stroke Unit, University of Perugia, Italy
Tel +39 075 578 6424
Fax +39 075 578 2436
Email cecila.becattini@unipg.it
Abstract: Anticoagulant drugs have an essential role in the prevention and treatment of 
  thromboembolic diseases. Currently available anticoagulants substantially reduce the incidence 
of thromboembolic events in a number of clinical conditions. However, these agents have 
limitations that strengthen the case for the development of new anticoagulants. An ideal 
  anticoagulant should be at least as effective as those currently in use, as well as safe, simple to 
use, and widely applicable.
The majority of new anticoagulants currently under investigation are small molecules with a 
selective and direct anti-Xa or antithrombin action, allowing oral administration in fixed doses. 
These new agents are in different phases of clinical development. The anti-Xa agent rivaroxa-
ban and the antithrombin agent dabigatran are already available for the prophylaxis of venous 
thromboembolism in some countries. Apixaban is in an advanced phase of clinical development 
and several anti-Xa agents are currently approaching phase III clinical trials. Promising results 
in terms of efficacy and safety profiles have been obtained with these agents in different clinical 
conditions. Differences in pharmacokinetics and pharmacodynamics could offer the potential 
for individualized anticoagulant therapies in the near future.
Keywords: anticoagulant therapy, antithrombotic therapy, anticoagulants, direct thrombin 
inhibitors, factor Xa inhibitors
Introduction
Antithrombotic prophylaxis is essential in order to reduce morbidity (symptomatic 
and asymptomatic venous thromboembolism) and mortality (overall mortality and 
fatal pulmonary embolism) in patients at risk for venous thromboembolism (VTE).1 
The risk of bleeding complications is the trade-off for antithrombotic efficacy with 
all anticoagulant agents.
Heparin, either unfractionated (UFH) or low molecular weight (LMWH), 
fondaparinux and warfarin have been shown to be very effective for the prophylaxis 
of VTE. However, the parenteral route of administration can be a limitation to the 
use of heparin or fondaparinux, while the need for laboratory monitoring and ongoing 
dose adjustment is the main limitation to the use of warfarin.
Newer anticoagulant agents with the potential for oral administration in fixed 
doses without the need for regular laboratory monitoring and dose adjustments, 
or significant food and drug interactions, should improve the use of antithrom-
botic prophylaxis. Indeed, nearly half of the patients undergoing major surgery 
or hospitalized for medical illnesses do not receive appropriate antithrombotic 
prophylaxis.2Drug Design, Development and Therapy 2010:4 50
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Table 1 Risk stratification for the incidence of VTE
Risk level  Distal DVT  Prox DVT  Fatal PE  DVT total  Patients  Antithrombotic 
  prophylaxis
Low 10% 1% 0.1% 10% Minor surgery in mobile  
patients (eg, arthroscopic  
surgery)
Prophylaxis 
  recommended only for 
patients with additional 
risk factors
10% Medical patients who are  
fully mobile
No prophylaxis 
  recommended
Moderate 10%–40% 1%–10% 0.1%–1% 10%–40% General, gynecologic,  
urologic surgery
LMWH, UFH or 
fondaparinux
10%–40% Medical patients, bed  
rest, sick
LMWH, UFH 
or fondaparinux 
  recommended for acutely 
ill hospitalized medical 
patients with additional 
risk factors*
High 40%–80% 10%–30% 1% 40%–80% Hip or knee arthroplasty LMWH, fondaparinux or 
adjusted-dose vitamin K 
antagonists
40%–80% Hip fracture surgery
        40%–80%  Major trauma, spinal  
cord injury
LMWH or UFH 
*Congestive heart failure, severe respiratory disease or who are confined to bed.
Abbreviations: DVT, deep vein thrombosis; LMWH, low molecular weight heparin; prox, proximal; PE, pulmonary embolism; UFH, unfractionated heparin.
Several new anticoagulant agents are currently in various 
phases of clinical development for the prophylaxis of VTE. 
This paper reviews the evidence for the efficacy and safety 
of the new anticoagulants for VTE prophylaxis in different 
clinical settings.
Risk stratification
Risk stratification is essential to identify candidates for 
antithrombotic prophylaxis (Table 1). VTE complications 
occur in 10% to 40% of patients admitted with a medical 
illness or undergoing general surgery, and in 40% to 60% 
of patients undergoing orthopedic surgery.1 The risk of VTE 
varies according to both patient-related and surgery-related 
risk factors. Patient-related risk factors include age, obesity, 
hormonal therapy, cancer, previous VTE, molecular throm-
bophilia, and chronic venous insufficiency. Surgery-related 
risk factors include type of surgery (eg, general, orthopedic, 
minor, major), length of surgery, and type of anesthesia. 
An individual’s risk of VTE increases in the presence of 
multiple risk factors. The duration of postoperative immo-
bilization and the occurrence of perioperative complications 
are additional risk factors for VTE in patients undergoing 
surgery.3
Major orthopedic surgery, eg, elective total knee replace-
ment (TKR), hip replacement (THR) and hip fracture repair 
put patients at highest risk of VTE complications. Pulmonary 
embolism (PE) is the main cause of death in these patients, 
and is the most common cause of readmission to the hospital 
following THR.4 However, fatal PE is uncommon after major 
orthopedic surgery if antithrombotic prophylaxis is used.5,6 
Minor arthroscopic procedures are associated with a lower 
risk of VTE than conventional orthopedic surgery.7
Patients hospitalized for a medical illness have an approxi-
mately eight-fold risk of VTE compared with the general 
population.8,9 VTE, proximal DVT, and fatal VTE occur in 
10% to 20%, 4% to 5%, and 1% of all patients hospitalized 
for medical illnesses, respectively.7,10–11 Previous VTE, stroke, 
heart failure, chronic obstructive.pulmonary disease, sepsis, 
and bed rest are risk factors for VTE in medical patients.10 The 
incidence of VTE in patients with cancer varies from 4% to 
20%, and is a leading cause of death in these patients.12,13 The 
risk of VTE in cancer patients is higher while in hospital for 
medical illnesses, during chemotherapy, and/or surgery.14–16
New anticoagulants
New anticoagulant agents under clinical development have 
been developed using advanced molecular technology that 
enables their effect to be targeted to a selected step or enzyme 
in the coagulation cascade.17–19 The large majority of new 
anticoagulants under clinical development are oral anti-Xa 
or anti-thrombin agents. Pharmacodynamic features of the 
newer anticoagulants are shown in Table 2.Drug Design, Development and Therapy 2010:4 51
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Orthopedic surgery: Clinical trials 
with new anti-Xa agents
A number of new anti-Xa and anti-thrombin agents are cur-
rently under evaluation for the prophylaxis of VTE in patients 
undergoing orthopedic surgery.
Rivaroxaban
Three Phase II, randomized, dose-ranging studies have been 
performed with rivaroxaban (initiated 6–8 hours post-sur-
gery) in comparison with enoxaparin (using European or 
North American dosing regimens) in patients undergoing 
major orthopedic surgery (see Table 3). Two studies included 
patients undergoing THR and one study included patients 
undergoing TKR.34–36 The primary efficacy endpoint used in 
these studies was the composite of any DVT (proximal and/or 
distal), confirmed nonfatal PE, and all-cause mortality. In all 
studies treatment was continued until mandatory bilateral 
venography 5–9 days after surgery. Based on the results of 
these studies, the 10 mg once daily regimen of rivaroxaban 
was selected for investigation in Phase III studies.
The Phase III development program for rivaroxaban 
comprised four Phase III clinical trials, known as the 
  REgulation of Coagulation in major Orthopedic surgery 
reducing the Risk of DVT and PE (RECORD) studies, 
assessing the efficacy and safety of rivaroxaban 10 mg once 
daily compared with enoxaparin given at US or European 
doses. The primary composite efficacy endpoint of the 
RECORD studies was any DVT, nonfatal PE, or death from 
any cause. The RECORD 1 and RECORD 3 studies showed 
that rivaroxaban started postoperatively was significantly 
more effective than enoxaparin started preoperatively in 
patients undergoing THR and TKR.37–38 The absolute risk 
reduction of the primary endpoint was 2.6% at 36 days in 
RECORD 1 and 9.2% at two weeks in RECORD 3, with 
similar safety profiles. In RECORD 2, extended (five-week) 
prophylaxis with rivaroxaban was compared with short-
term (10–14 days) prophylaxis with enoxaparin in patients 
undergoing THR.39 As expected, the study showed that 
extended prophylaxis with rivaroxaban is superior to short-
term prophylaxis with enoxaparin in patients undergoing 
THR, without safety concerns. In RECORD 4, rivaroxaban 
was compared with enoxaparin, both started postopera-
tively and continued for 10–14 days in patients undergoing 
TKR.40 Rivaroxaban was significantly more effective than 
enoxaparin (incidence of primary efficacy outcome at day 
17 after surgery 6.9% and 10.1% in patients randomized 
to rivaroxaban or enoxaparin, respectively) in patients 
undergoing TKR. Major bleeding occurred in 0.7% patients 
randomized to rivaroxaban and in 0.3% patients randomized 
to enoxaparin.
A pooled analysis of the four RECORD studies has been 
performed to assess the clinical benefit of rivaroxaban com-
pared with enoxaparin in terms of hard clinical endpoints. 
The analysis showed that rivaroxaban is more effective 
than enoxaparin for the prevention of symptomatic VTE 
and all-cause death in patients undergoing major orthope-
dic surgery, irrespective of age, weight, gender, or renal 
function.41 Rivaroxaban reduced the composite endpoint of 
symptomatic VTE, cardiovascular events, all-cause mortal-
ity, and major bleeding significantly more than enoxaparin 
(P = 0.004). A similar effect was observed in the incidence 
of symptomatic VTE and/or death at 10–14 days (0.47% 
versus 0.97%; P = 0.001) and for the total study duration 
(0.81% versus 1.63%; P  0.001). However, rivaroxaban was 
associated with a higher incidence of major bleeding than 
enoxaparin at 10–14 days (0.34% versus 0.21%) and for the 
total study duration (0.44% versus 0.27%).42 Further stud-
ies should address the issue of the cardiovascular rebound 
phenomenon to establish the safety of rivaroxaban.43 Based 
on the results of the RECORD studies, rivaroxaban has been 
recently licensed for the prevention of VTE after elective 
hip and knee replacement in Europe and Canada. A Phase 
IV clinical trial is ongoing to assess additional information 
on the risk-benefit profile of rivaroxaban (NCT00831714 
www.clinicaltrial.gov).
Apixaban
Apixaban was compared with enoxaparin (30 mg twice daily) 
and warfarin (INR 1.8–3.0) in a dose-finding study in 1238 
patients undergoing TKR.44 All apixaban groups had lower 
primary efficacy event rates (composite of VTE [assessed 
by mandatory venography] and all-cause mortality during 
treatment) than either comparator. Based on these results, 
apixaban 2.5 mg twice daily was selected for Phase III 
development.
Three Phase III trials have been designed to explore the 
efficacy and safety of apixaban for the prevention of throm-
boembolism after major orthopedic surgery (ADVANCE 
program). The primary efficacy outcome of these studies 
was the composite of DVT (by venography or diagnosed 
on symptoms), PE, and death from any cause during the 
treatment period. In the ADVANCE 1 trial apixaban did not 
meet the criteria for noninferiority compared with enoxa-
parin for prevention of VTE in patients undergoing TKR.45 
The primary efficacy outcome occurred in 9% of patients 
in the apixaban group and in 8.8% in the enoxaparin group. Drug Design, Development and Therapy 2010:4 53
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Major or clinically relevant nonmajor bleeding occurred in 
2.9% of patients in the apixaban group and in 4.3% in the 
enoxaparin group (P = 0.03). Major bleeding occurred in 
0.7% of patients in the apixaban group and in 1.4% in the 
enoxaparin group (P = 0.053).
In the ADVANCE 2 trial apixaban was compared with 
enoxaparin in patients undergoing TKR.46 The incidence of 
the primary efficacy outcome was 15.1% in the apixaban 
group and 24.4% in the enoxaparin group (relative risk 0.62, 
95% CI 0.51–0.74). Proximal DVT, symptomatic nonfatal 
PE, and VTE-related death occurred in 1.1% of patients given 
apixaban and in 2.2% of patients given enoxaparin (relative 
risk 0.50, 95% CI 0.26–0.97). Clinically relevant bleeding 
(major or clinically relevant nonmajor) occurred in 3.5% 
and 4.8% of the patients given apixaban and enoxaparin, 
respectively (P = 0.09). A Phase III randomized, double-blind 
study has been recently completed aimed at assessing the 
relative efficacy and safety of apixaban and enoxaparin for 
35 days in patients undergoing elective THR surgery (www.
clinicaltrial.gov NCT00423319).
New anti-Xa in Phase II trials
The oral anti-Xa betrixaban has been compared with 
enoxaparin, both started postoperatively in patients under-
going TKR.47 DVT on mandatory unilateral venography or 
symptomatic proximal, or PE was reported through to day 
14 in 20%, 15%, and 10% of patients receiving increasing 
doses of betrixaban or enoxaparin, respectively. No bleed-
ing complications were reported in the betrixaban 15 mg 
group. Major bleeding occurred in 2.3% of patients in the 
enoxaparin group.
Two Phase II studies have explored the efficacy and safety 
of edoxaban for the prevention of VTE in major orthopedic 
surgery. Edoxaban reduced the incidence of VTE in a dose-
dependent fashion in comparison with placebo, without a 
significant increase in bleeding complications in patients 
undergoing TKR.48 Edoxaban was compared with dalteparin 
in patients undergoing THR.49 VTE occurred in 43.3% of 
patients in the dalteparin group and in 28.2%, 21.2%, 15.2%, 
and 10.6% of patients receiving edoxaban, respectively. No 
bleeding was reported in the dalteparin group. The incidence 
of major or clinically significant nonmajor bleeding in the 
edoxaban groups ranged from 1.6% with lower doses to 2.3% 
for higher doses.
The efficacy and safety of YM150 for the prevention 
of VTE in patients undergoing THR was investigated in a 
Phase II study.27 Patients were randomized to once-daily 
YM150 starting 6–10 hours after hip replacement or to 
receive subcutaneous enoxaparin for 7–10 days. A signifi-
cant dose-related trend in the incidence of VTE (confirmed 
symptomatic events and/or positive bilateral venography on 
the last treatment day) was observed with YM150. Three 
clinically relevant nonmajor bleedings were observed, one in 
the 3 mg and two in the 10 mg YM150 dose groups. The 
Phase II ONYX-2 study confirmed a significant decrease 
in the incidence of DVT, symptomatic VTE, PE, and death 
with increasing doses of YM150 in patients undergoing 
THR surgery.50 A number of Phase II and Phase III studies 
have been designed testing this agent, of which some are 
completed and some are currently ongoing. The aim of these 
studies is to evaluate the efficacy and safety of various doses 
of YM150 for the prevention of VTE in patients undergoing 
major orthopedic surgery in comparison with enoxaparin or 
warfarin (NCT00902928, NCT00913120, NCT00937911, 
NCT00408239, NCT00917254, NCT00595426 www.clinical 
trials.gov).
The oral anti-Xa razaxaban has been compared with twice 
daily 30 mg enoxaparin in patients undergoing elective knee 
surgery.29 Razaxaban was effective at any evaluated dos-
age, but highest doses were associated with more bleedings 
than enoxaparin. No further study has been conducted with 
razaxaban.
In patients undergoing THR or TKR, prophylaxis with 
LY517717 resulted in a dose-dependent decrease in the 
incidence of VTE. The incidences of overall, symptom-
atic, or asymptomatic VTE was 19%, 19%, and 16% with 
increasing doses of LY517717, respectively, compared 
with 21% for enoxaparin. All the doses of LY517717 met 
the predefined criteria for noninferiority compared with 
enoxaparin for the prevention of VTE after TKR or THR, 
with similar rates of bleeding complications.28 No studies 
are currently ongoing with this agent in patients undergoing 
orthopedic surgery.
In a dose-finding study, the efficacy of different doses 
of eribaxaban has been compared with that of enoxaparin 
in patients undergoing TKR.30 VTE occurred in 37%, 37%, 
29%, 19%, 14%, 1.4%, and 11% of patients receiving 
increasing doses of eribaxaban, respectively, compared with 
18% of patients receiving enoxaparin. This study showed a 
nonsignificant dose-related increase in the incidence of total 
bleeding, mainly accounted for by minor bleeding.
A dose-finding study is currently underway to assess the 
efficacy and safety of TAK-442 in comparison with enoxa-
parin for the prevention of VTE after TKR (NCT00641732 
www.clinicaltrial.gov). A Phase II study has also been 
designed to assess the efficacy and safety of GW813893 in Drug Design, Development and Therapy 2010:4 56
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the prophylaxis of VTE following TKR. (NCT00541320 
www.clinicaltrial.gov).
In a Phase II study, 690 patients undergoing TKR 
surgery were randomized to AVE5026 or enoxaparin.32 
A significant dose-response effect was observed with 
AVE5026, the incidence of total VTE ranging from 44.1% 
to 5.3%. VTE occurred in 35.8% of patients receiving 
enoxaparin. The three highest doses of AVE5026 were 
significantly more effective than enoxaparin in reducing 
VTE. Also, a significant dose-response for AVE5026 was 
seen for major bleeding. The 20 mg dose of AVE5026 was 
selected for future investigation in Phase III studies of the 
prevention of VTE in patients undergoing THR surgery and 
hip fracture surgery (NCT00697099, NCT00721760 www.
clinicaltrial.gov). The results of a multicenter, randomized, 
double-blind study comparing the efficacy and safety of 
AVE5026 with that of enoxaparin for the prevention of VTE 
in patients undergoing elective knee replacement surgery 
will be available in the near future (NCT00718224 www.
clinicaltrial.gov).
Clinical trials with the new 
antithrombin agent dabigatran
The clinical development program for dabigatran in ortho-
pedic surgery is almost completed (Table 4). The Phase II 
program comprises the dose-finding BISTRO I and II stud-
ies.51,52 A significant dose-dependent decrease in VTE and 
an increase in major bleeding were observed with increasing 
doses of dabigatran in patients undergoing THR or TKR. 
The 150 mg and 220 mg once daily doses were selected for 
clinical development in the Phase III program.
In the RE-NOVATE study, dabigatran (starting 1–4 hours 
after surgery with half the dose) was compared with enoxa-
parin (starting the evening before surgery) both given for 
28–35 days in 3494 patients undergoing THR.53 The composite 
of total VTE (symptomatic and asymptomatic) and death 
from all causes occurred in 6.7% patients in the enoxaparin 
group versus 6.0% and 8.6% of the patients in the dabigatran 
220 mg and 150 mg groups, respectively. Both dabigatran 
doses met the criteria for noninferiority in comparison with 
enoxaparin, with no significant difference in major bleeding. 
In the RE-MODEL study 2076 patients undergoing TKR were 
randomized to receive dabigatran (starting 1–4 hours after 
surgery with half the dose) or subcutaneous enoxaparin.54 In 
this study, total VTE (symptomatic and asymptomatic) and 
death during treatment occurred in 37.7% of the patients 
in the enoxaparin group, compared with 36.4% and 40.5% 
of the patients in the dabigatran 220 mg or 150 mg groups, 
respectively. Both doses were found to be noninferior in 
comparison with enoxaparin. The incidence of major bleeding 
was similar across the three groups.
In the RE-MOBILIZE study, dabigatran (starting after 
surgery with half the dose) was compared with enoxaparin 
for 12 to 15 days after TKR.55 Total VTE and all-cause 
mortality occurred in 31% and 34% of the patients in the 
dabigatran 220 mg and in the 150 mg groups, respectively, 
compared with 25% of patients receiving enoxaparin. 
In this study dabigatran did not achieve the criteria for 
noninferiority. The safety profile was similar in all three 
groups (0.6% in dabigatran groups and 1.4% in enoxaparin 
groups).
The results of the RE-MODEL, RE-NOVATE and 
RE-MOBILIZE studies were recently pooled in a meta-
analysis that confirmed the noninferiority of dabigatran in 
comparison with enoxaparin 40 mg once daily in patients 
undergoing major orthopedic surgery, with a similar safety 
profile.56 No significant differences in the incidence of liver 
enzyme elevation or coronary events between the treatment 
groups were observed in the Phase III development program. 
A trend toward increased gastrointestinal bleeding has been 
suggested with dabigatran in long-term indications.
The clinical development of dabigatran in orthopedic 
surgery is continuing with a Phase III study on the efficacy 
and safety of dabigatran (110 mg on the day of surgery fol-
lowed by 220 mg once daily), compared with enoxaparin 
40 mg for 28–35 days, in patients undergoing elective THR 
(NCT00657150 www.clinicaltrials.gov). In another study, 
patients undergoing TKR will receive in-hospital prophylaxis 
with nadroparin and dabigatran (110 mg twice daily) for 
10 days after discharge from hospital (NCT00868179 www.
clinicaltrials.gov).
Observational Phase IV studies of the safety and efficacy 
of dabigatran in predefined subpopulations of patients at 
increased risk of bleeding or VTE or with moderate renal 
impairment (creatinine clearance 30–50 mL/min) in a 
Mexican population are also about to start (NCT00847301, 
NCT00846807, NCT00967447 www.clinicaltrials.gov). 
Dabigatran has recently been licensed in Europe and in 
Canada for thromboprophylaxis in patients undergoing hip 
and knee replacement.
Prevention of VTE in general 
surgical patients
Two studies are currently ongoing aimed at assessing the 
efficacy and safety of new anticoagulant agents in the 
prevention of VTE in patients undergoing major abdominal Drug Design, Development and Therapy 2010:4 57
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surgery. One is a Phase III, randomized, double-blind study 
comparing the efficacy and safety of AVE5026 (given 
once daily by subcutaneous injection) with enoxaparin 
(40 mg once daily) (NCT00679588 www.clinicaltrials.
gov, see Table 5).
The other is a Phase III open-label study aimed at evalu-
ating the efficacy and safety of the oral anti-Xa YM150 for 
prevention of VTE and all-cause death in patients undergoing 
major abdominal surgery in comparison with mechanical 
prophylaxis (NCT00942435 www.clinicaltrials.gov).
Prevention of VTE  
in medical patients
Several studies are currently ongoing or are about to start 
with new anticoagulant agents for the prevention of VTE in 
patients hospitalized for acute medical illnesses.
A Phase III study has been recently completed and the 
results will be available in the near future for AVE5026 
in comparison with enoxaparin for the prevention of 
VTE in patients hospitalized for acute medical illnesses 
(NCT00714597 www.clinicaltrial.gov).
A randomized, double-blind trial is currently ongoing 
aimed at comparing the efficacy and safety of rivaroxaban 
(10 mg once daily) given for 31–39 days with that of enoxa-
parin (40 mg once daily) given for 6–14 days (NCT00571649 
www.clinicaltrial.gov). The incidence of any VTE is diag-
nosed by compression ultrasonography is evaluated at the 
end of the treatment period.
A Phase III double blind study is evaluating apixaban 
(2.5 mg twice daily) given for 30 days plus subcutaneous 
placebo for 6–14 days, with respect to enoxaparin (40 mg 
once daily) given for 6–14 days plus oral placebo for 30 days, 
in patients hospitalized for medical illnesses (NCT00457002 
www.clinicaltrial.gov).
Cancer patients
Several clinical trials have compared different agents for 
the prophylaxis of VTE in patients undergoing surgery for 
cancer or evaluated the need for extended out-of-hospital 
prophylaxis in these patients.57–60
A Phase II study is currently underway to assess whether 
apixaban (5 mg once daily for 12 weeks) administered to 
Table 4 Efficacy and safety results with new II inhibitors in different clinical indications
Trial/drug 
 
Phase 
 
Drug 
 
Comparator 
 
Indication 
 
Primary 
efficacy 
  outcome
Major bleeding  
definition 
Results 
 
BISTRO I51 II Dabigatran 12.5, 25, 
50,100,150, 200,  
300 mg bid or 150, 
300 mg od
No comparator THR Any DVT Standard Effective with no 
dose effect no 
major bleedings
BISTRO II52 II Dabigatran 50,150, 
225 mg bid or  
300 mg od
Enoxaparin  
40 mg od
THR TKR Any VTE Standard + surgical 
or nonsurgical site 
bleeding warranting 
treatment cessation 
or re-operation
Dose-dependent 
efficacy and 
safety VTE lower 
in 150, 225 mg 
bid and 300 mg 
od
RE-MODEL54 III Dabigatran 150 or 
220 mg 28–35 days
Enoxaparin  
40 mg 6–10 days
TKR Any VTE and 
death from  
all causes
Noninferiority 
of dabigatran 
similar safety
RE-MOBILIZE55 III Dabigatran  
150–220 mg  
28–35 days
Enoxaparin  
30 mg bid 12–15 days
TKR Inferiority of 
dabigatran 
  similar safety
RE-NOVATE53 III Dabigatran  
150–220 mg  
28–35 days
Enoxaparin  
40 mg 28–35 days
THR Noninferiority 
of dabigatran 
similar safety
Dabigatran 
  metanalysis56 
 
  
 
 
Dabigatran  
220 mg, 150 mg 
 
Enoxaparin 40 mg 
  Enoxaparin 30 mg 
 
TKR THR 
 
 
Any VTE and 
death from  
all causes 
 
 
 
Noninferior 
to enoxaparin 
40 mg Similar 
safety
Notes: Standard: clinically overt bleeding associated with a fall in hemoglobin 2 g/dL within 24 hours, leading to transfusion of 2 units of blood; fatal bleeding; bleeding into 
a critical organ (including retroperitoneal, intracranial, intraocular, or intraspinal bleeding).
Abbreviations: THR, total hip replacement; TKR, total knee replacement; VTE, venous thromboembolism.Drug Design, Development and Therapy 2010:4 58
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patients with advanced or metastatic cancer for the prevention 
of VTE will be well tolerated compared with placebo 
(NCT00320255 www.clinicaltrial.gov).
A Phase III study comparing the efficacy and safety of 
AVE5026 (once daily subcutaneous injections) with placebo 
for the prevention of VTE in high-risk cancer patients under-
going chemotherapy is currently ongoing (NCT00694382 
www.clinicaltrial.gov).
Conclusions
Several new anticoagulant drugs are currently in clinical 
development for the prophylaxis of VTE. New agents have 
the potential to make anticoagulant treatment and prophy-
laxis easier as they are mostly available for oral administra-
tion in fixed doses, have short half-lives, and rapid onset 
of action. Given their different mechanisms of action and 
pharmacokinetic properties, the new anticoagulants also 
offer the potential for anticoagulation to be tailored for 
individual patients. Whether different mechanisms of action 
(eg, anti-Xa or anti-IIa effect) can influence the efficacy 
and safety profiles of new anticoagulants is currently only 
speculative.
The real advantage of new anticoagulants is expected 
for chronic indications more than for time-limited ones. It is 
conceivable that the use of new anticoagulants for the prophy-
laxis of VTE will increase after their approval for long-term 
indications.
If these new agents complete clinical development and 
become available for clinical use, clinicians will have the 
potential to choose the optimal anticoagulant regimen on an 
individual patient basis, taking into account not only safety, 
efficacy, and the clinical setting, but also patient characteristics, 
including age, renal failure, and liver disease.
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